MON-056 Leucine-Rich a-2-Glycoprotein 1 increased Peripheral arterial occlusive disease risk in end-stage renal disease

Abstract

Plasma Leucine-Rich a-2-Glycoprotein 1(LRG1) as a novel serum biomarker for inflammation and angiogenetic diseases. Patients with end-stage renal disease (ESRD) are associated with several health-related adverse outcomes including inflammation, atherosclerosis and premature mortality in individuals. Whether level of Plasma Leucine-Rich a-2-Glycoprotein 1 may associate with the clinical status of hemodialysis patients is unknown. The immunity in ESRD study (iESRD) recruited 169 hemodialysis patients from southern Taiwan. By history taking and detailed chart reviews, baseline co-morbidities were recorded. Peripheral blood was sampled before hemodialysis session and processed immediately. Plasma levels of LRG1 and high-sensitivity C reactive protein were determined by ELISA. Peripheral blood monocyte and T cell differentiation subsets 1 may by multicolor flow cytometry. Among these patients, 100% were LRG-1-seropositive. In a multivariate-adjusted logistic regression model, higher LRG1 tertile was significantly associated with Peripheral arterial occlusive disease(PAOD) (odds ratio = 3.49)after adjusting for gender, hemoglobin, DM, hypertension, and the level hs-CRP. LRG1 exhibit lower TCM percentages of CD4+ and CD8+ T cells but also lower TNAIVE percentages of CD8+ T cells. Similar trends were observed when the absolute cell number of each T cell subsets was analyzed. Level of LRG-1 positively correlated with both IL-6, CRP and WBC, indicating the accumulation of these cytokines participate in the progression of atherosclerosis. LRG-1positively correlates with the existence of the Peripheral arterial occlusive disease in ESRD patients. Role of LRG-1 and the associated inflammation response should the in the pathogenesis of atherosclerosis in this patient population.